STOCK TITAN
  1. Home
  2. Sec-filings
  3. BMY
  4. [8-K] BRISTOL MYERS SQUIBB CO Reports Material Event

Bristol Myers Squibb (NYSE: BMY) lifts 2026 revenue and EPS guidance

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Bristol Myers Squibb Company reported second-quarter 2026 results with total revenue of $12,973 million, up 6% year over year. The Growth Portfolio generated $7,560 million, up 15%, while the Legacy Portfolio was $5,422 million, down 4% as generic erosion offset Eliquis growth.

GAAP diluted EPS rose to $1.62 from $0.64, and non-GAAP diluted EPS increased to $2.04 from $1.46. Eliquis revenue grew 22% to $4,481 million, while Revlimid and Pomalyst declined sharply. Net income attributable to Bristol Myers Squibb was $3,317 million.

The company raised its 2026 non-GAAP revenue outlook to $49.0–$50.0 billion and increased non-GAAP EPS guidance to $6.75–$7.00, reflecting broad portfolio momentum and higher Eliquis expectations. Guidance assumes 20–25% worldwide Eliquis revenue growth and operating expenses of about $16.5 billion.

Positive

  • Raised 2026 non-GAAP revenue guidance to $49.0–$50.0 billion and diluted EPS guidance to $6.75–$7.00, indicating materially higher expected full-year performance.
  • Growth Portfolio revenue increased 15% to $7,560 million, outpacing overall company growth and driven by newer medicines such as Reblozyl, Breyanzi, Camzyos and Opdualag.

Negative

  • None.

Filing Explained

As of June 30, 2026, BMS reported $11.5 billion in cash and securities against $43.1 billion in debt, with $5 billion of repurchase authorization remaining.

Bristol Myers Squibb used this Form 8-K to report its second-quarter results, furnishing the earnings release under Item 2.02; the filing also furnishes a presentation under Item 7.01, which it says is not deemed filed under the Exchange Act. The disclosure therefore records the results and outlook update, while giving the presentation a different filing status.

As of June 30, 2026, the company reported $11.5 billion of cash, cash equivalents and marketable debt securities against about $43.1 billion of total debt, producing a reported net debt position. The presentation also identified about $5 billion of remaining share-repurchase authorization as of that date; this is stated as authorization capacity, not as a reported amount repurchased.

On the pipeline side, the FDA accepted Reblozyl's supplemental application on July 30, 2026 with a PDUFA date of March 11, 2027, while mezigdomide's application had been accepted with a PDUFA date of May 13, 2027. Those are regulatory-review milestones, not approvals or commercial launches.

The next specified checkpoints are the FDA dates for Reblozyl and mezigdomide; the financial guidance also excludes future acquisitions, divestitures and not-yet-quantified specified items.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Total Revenues $12,973 million Second quarter 2026 total revenues, up 6% versus Q2 2025
Q2 2026 Growth Portfolio Revenue $7,560 million Growth Portfolio revenues in Q2 2026, up 15% year over year
Q2 2026 Legacy Portfolio Revenue $5,422 million Legacy Portfolio revenues in Q2 2026, down 4% year over year
Q2 2026 GAAP Diluted EPS $1.62 GAAP diluted earnings per share for Q2 2026 versus $0.64 in Q2 2025
Q2 2026 Non-GAAP Diluted EPS $2.04 Non-GAAP diluted EPS for Q2 2026 versus $1.46 in Q2 2025
2026 Non-GAAP Revenue Guidance $49.0–$50.0 billion Updated full-year 2026 non-GAAP total revenue guidance range
2026 Non-GAAP EPS Guidance $6.75–$7.00 Updated full-year 2026 diluted non-GAAP EPS guidance range
Net Debt Position as of June 30, 2026 $(31,656) million Net debt based on cash, cash equivalents, marketable securities and total debt
Growth Portfolio financial
"Growth Portfolio revenues of $7.6 billion increased 15%, or 14% Ex-FX."
Legacy Portfolio financial
"Legacy Portfolio revenues of $5.4 billion decreased 4%, or 5% Ex-FX."
Acquired IPRD financial
"Acquired IPRD charges and licensing income net impact on earnings/(loss) per share."
PDUFA date regulatory
"The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027."
PDUFA date is the deadline the U.S. Food and Drug Administration sets to complete its review of a drug or biologic application and decide whether to approve it. Investors watch it like a court verdict date: the decision can unlock sales and growth if approved or sharply reduce expected value if denied, so markets often move significantly as the date approaches or when the outcome is announced.
CELMoD medical
"Mezigdomide is the second BMS CELMoD to be granted a PDUFA date this year."
Ex-FX financial
"Second quarter revenues increased 6% (+5% Ex-FX) to $13.0 billion."
Ex-fx means a financial number has been shown excluding the effects of changes in foreign exchange rates. It isolates performance from currency movements so revenue or profit figures reflect underlying business activity rather than gains or losses caused by converting money from one currency to another. Think of it like comparing the size of an apple harvest before and after a change in the scale used to weigh apples—ex-fx keeps the harvest itself constant so you see the real trend.
Offering Type IPO/secondary/shelf/ATM

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Bristol Myers Squibb (BMY) revenues in Q2 2026?
Bristol Myers Squibb reported Q2 2026 total revenues of $12,973 million, an increase of 6% versus Q2 2025. U.S. revenue was $8,991 million and international revenue was $3,982 million, each also up 6%, or 5% on an Ex-FX basis.

How did Bristol Myers Squibb (BMY) earnings per share change in Q2 2026?
GAAP diluted EPS rose to $1.62 in Q2 2026 from $0.64 a year earlier. Non-GAAP diluted EPS increased to $2.04 from $1.46, a 40% year-over-year increase, reflecting higher revenue, lower acquired IPRD charges and reduced amortization of acquired intangibles.

What is Bristol Myers Squibb (BMY) 2026 revenue and EPS guidance now?
The company raised 2026 non-GAAP revenue guidance to ~$49.0–$50.0 billion, up from ~$46.0–$47.5 billion. It also increased non-GAAP diluted EPS guidance to $6.75–$7.00, versus a prior $6.05–$6.35 range, while keeping gross margin and tax-rate assumptions unchanged.

How did Bristol Myers Squibb’s (BMY) Growth and Legacy Portfolios perform in Q2 2026?
In Q2 2026 the Growth Portfolio generated $7,560 million, up 15% (14% Ex-FX). The Legacy Portfolio delivered $5,422 million, down 4% (5% Ex-FX), as strong Eliquis growth was more than offset by steep declines in Revlimid and Pomalyst/Imnovid.

What notable pipeline or regulatory milestones did Bristol Myers Squibb (BMY) highlight?
The company reported FDA acceptance of a supplemental BLA for Reblozyl with a PDUFA date of March 11, 2027, and acceptance of an NDA for mezigdomide with a PDUFA date of May 13, 2027, alongside positive phase 3 data for iza-bren in oncology.
0000014272false00000142722026-07-302026-07-300000014272bmy:CommonStock0.10ParValueMember2026-07-302026-07-300000014272bmy:CelgeneContingentValueRightsMember2026-07-302026-07-300000014272bmy:A2.973NotesDue2030Member2026-07-302026-07-300000014272bmy:A3.363NotesDue2033Member2026-07-302026-07-300000014272bmy:A1.750Notesdue2035Member2026-07-302026-07-300000014272bmy:A3.857NotesDue2038Member2026-07-302026-07-300000014272bmy:A4.289NotesDue2045Member2026-07-302026-07-300000014272bmy:A4.581NotesDue2055Member2026-07-302026-07-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________
FORM 8-K
_____________________________

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2026

_____________________________
BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)
_____________________________
Delaware001-0113622-0790350
(State or other jurisdiction of
incorporation or organization)		(Commission File Number)(I.R.S Employer
Identification No.)
Route 206 & Province Line Road, Princeton, New Jersey 08543
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code): (609) 252-4621
_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.10 Par ValueBMYNew York Stock Exchange
Celgene Contingent Value RightsCELG RTNew York Stock Exchange
2.973% Notes due 2030BMY/30New York Stock Exchange
3.363% Notes due 2033BMY/33New York Stock Exchange
1.750% Notes due 2035BMY35New York Stock Exchange
3.857% Notes due 2038BMY/38New York Stock Exchange
4.289% Notes due 2045BMY/45New York Stock Exchange
4.581% Notes due 2055BMY/55New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 Results of Operations and Financial Condition.

On July 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the information contained in or connected to the Company's website is not deemed to be incorporated by reference in this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On July 30, 2026, the Company posted on its website at www.bms.com a presentation (the “Bristol Myers Presentation”) on certain financial and operating initiatives available for viewing during the Company’s conference call and webcast announcing its financial results for the second quarter of 2026 at 8:15 a.m. Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Earnings Press Release and the Bristol Myers Presentation include references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures and the reasons for the presentation of such non-GAAP financial measures, are available in the Earnings Press Release which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website at any time.

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:
Exhibit
No.		Description
99.1
Press release of Bristol-Myers Squibb Company dated July 30, 2026
99.2
Presentation Materials of Bristol-Myers Squibb Company dated July 30, 2026
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
BRISTOL-MYERS SQUIBB COMPANY
Dated: July 30, 2026
By: /s/ Amy Fallone
Name: Amy Fallone
Title:Senior Vice President and Corporate Secretary


Exhibit 99.1
bmslogo2a.jpg

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook
Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress

•Second quarter revenues increased 6% (+5% Ex-FX) to $13.0 billion
◦Growth Portfolio revenues increased 15% (+14% Ex-FX) to $7.6 billion
•GAAP EPS was $1.62 and non-GAAP EPS was $2.04
•Raising 2026 revenue guidance to a range of ~$49.0 billion to $50.0 billion; Increasing non-GAAP EPS range to $6.75 to $7.00
(PRINCETON, N.J., July 30, 2026) – Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2026.

“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "We are building from a position of strength and progressing a differentiated pipeline designed to generate long-term value. As a result of our consistent execution and continued momentum, we are raising our 2026 full-year outlook."


Second Quarter Results
$ in millions, except per share amounts20262025Change
Change Excl. FX**
Total Revenues$12,973 $12,269 6 %5 %
Earnings/(Loss) Per Share - GAAP*1.62 0.64 153 %N/A
Earnings/(Loss) Per Share - Non-GAAP*2.04 1.46 40 %N/A
Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Share 0.01 (0.57)N/AN/A
*GAAP and Non-GAAP earnings/(loss) per share include the net impact of Acquired IPRD charges and licensing income.
**See "Use of Non-GAAP Financial Information".


1

SECOND QUARTER RESULTS*
•Growth Portfolio revenues of $7.6 billion increased 15%, or 14% Ex-FX. Revenue growth was primarily driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag.
•Legacy Portfolio revenues of $5.4 billion decreased 4%, or 5% Ex-FX. Demand increased for Eliquis, which was more than offset by expected continued generic impacts across the remainder of the Legacy Portfolio.
•Total revenues of $13.0 billion increased 6%, or 5% Ex-FX.
◦U.S. revenues of $9.0 billion increased 6%.
◦International revenues of $4.0 billion increased 6%, or 5% Ex-FX.
*All comparisons are made versus the same period in 2025 unless otherwise stated.

SECOND QUARTER PRODUCT REVENUE HIGHLIGHTS(e)

($ amounts in millions)Quarter Ended June 30, 2026
% Change from Quarter Ended June 30, 2025
% Change from Quarter Ended June 30, 2025 Ex-FX**
 
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
Int'l
WW(d)
Growth Portfolio
Opdivo$1,417 $1,068 $2,485 (6)%1 %(3)%(1)%(4)%
Opdivo Qvantig206 55 261 >200%>200%>200%>200%>200%
Orencia801 233 1,034 13 %(8)%7 %(8)%7 %
Yervoy481 288 769 7 %4 %6 %2 %5 %
Reblozyl593 142 735 31 %24 %29 %24 %29 %
Breyanzi354 131 484 39 %48 %41 %47 %41 %
Opdualag294 55 349 17 %72 %23 %65 %22 %
Camzyos310 105 416 45 %129 %60 %124 %59 %
Zeposia116 53 169 11 %17 %12 %14 %12 %
Sotyktu51 36 87 19 %30 %23 %27 %23 %
Krazati47 8 55 1 %>200%14 %>200%14 %
Cobenfy60 3 63 73 %>200%81 %>200%81 %
Other Growth Products(a)
244 409 653 (1)%32 %17 %32 %17 %
Total Growth Portfolio
4,974 2,585 7,560 14 %15 %15 %13 %14 %
Legacy Portfolio
Eliquis3,357 1,124 4,481 27 %9 %22 %7 %21 %
Revlimid352 72 425 (52)%(32)%(49)%(30)%(49)%
Pomalyst/Imnovid131 73 204 (78)%(41)%(71)%(38)%(71)%
Sprycel52 35 88 (23)%(32)%(27)%(30)%(26)%
Abraxane12 43 55 (62)%(40)%(47)%(40)%(47)%
Other Legacy Products(b)
112 58 170 12 %(53)%(24)%(53)%(24)%
Total Legacy Portfolio 4,017 1,405 5,422 (4)%(7)%(4)%(7)%(5)%
Other Revenue(c)
— (9)(9)N/AN/AN/AN/AN/A
Total Revenues$8,991 $3,982 $12,973 6 %6 %6 %5 %5 %
**    See "Use of Non-GAAP Financial Information".
(a)    Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.
(b)    Includes other mature brands.
(c)    Includes revenue hedging activities in 2026.
(d)    Worldwide (WW) includes U.S. and International (Int'l).
(e)     For the above table and all subsequent tables, certain totals may not sum due to rounding. Percentages have been calculated using unrounded amounts.
2

SECOND QUARTER COST & EXPENSES
The table below presents selected line-item information.

GAAPNon-GAAP**
Three months ended June 30,Three months ended June 30,
($ amounts in millions)
2026
2025
Change
2026
2025
Change
Cost of products sold
$3,726 $3,372 11%$3,711 $3,356 11%
Gross margin
71.3 %72.5 %(120) bps71.4 %72.6 %(120) bps
Selling, general and administrative
1,826 1,713 7%1,826 1,691 8%
Research and development
2,959 2,580 15%2,316 2,263 2%
Acquired IPRD(a)
— 1,508 (100)%— 1,508 (100)%
Amortization of acquired intangible assets
437 830 (47)%— — N/A
Other (income)/expense, net
(61)494 NM126 (108)NM
Effective tax rate
18.8 %25.9 %(710) bps16.5 %16.1 %40 bps
** See "Use of Non-GAAP Financial Information" and refer to the Specified Items schedule below for further detail.
NM Not meaningful.
(a) Non-GAAP Acquired IPRD does not include adjustments to GAAP Acquired IPRD.

•Gross margin decreased from 72.5% to 71.3% on a GAAP basis, and from 72.6% to 71.4% on a non-GAAP basis, primarily reflecting a change in product mix.
•Selling, general and administrative expenses of $1.8 billion increased 7% on a GAAP basis and 8% on a non-GAAP basis, primarily driven by investments in new product launches.
•Research and development expenses of $3.0 billion increased 15% on a GAAP basis, primarily driven by the purchase of a priority review voucher and higher IPRD impairment charges in 2026. Non-GAAP research and development expenses of $2.3 billion increased 2%.
•Amortization of acquired intangible assets of $437 million decreased 47% on a GAAP basis, primarily driven by lower amortization expense related to Pomalyst.
•Other (income)/expense, net of $(61) million and $126 million on a GAAP and non-GAAP basis, respectively, reflects the expiry of royalty income on diabetes products at the end of 2025.
•Effective tax rate decreased from 25.9% to 18.8% on a GAAP basis and increased from 16.1% to 16.5% on a non-GAAP basis, primarily driven by jurisdictional earnings mix.
•Net income attributable to Bristol Myers Squibb of $3.3 billion, or $1.62 per share, increased from $1.3 billion, or $0.64 per share, on a GAAP basis. On a non-GAAP basis, net income attributable to Bristol Myers Squibb of $4.2 billion, or $2.04 per share, increased from $3.0 billion, or $1.46 per share. GAAP and non-GAAP EPS include the impacts of Acquired IPRD charges and licensing income.
3

PRODUCT AND PIPELINE UPDATES
Entries organized by date and inclusive of second quarter and recent updates.
Asset(s)
Date Announced
Milestone
Reblozyl® (luspatercept)
July 30
The U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions. The acceptance was supported by results from the Phase 3 INDEPENDENCE study. The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027.
mezigdomideJuly 13
The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027. The filing was based on the positive results from the Phase 3 SUCCESSOR-2 trial.

Mezigdomide is the second BMS CELMoD to be granted a PDUFA date this year for an RRMM indication, joining iberdomide, which has a PDUFA date of August 17, 2026.
izalontamab brengitecan
(iza-bren)		June 2
Announced with SystImmune that SystImmune's parent company, Sichuan Biokin Pharmaceutical Co., Ltd., reported positive results from prespecified interim analyses of two Phase 3 studies evaluating iza-bren. In the studies, iza-bren achieved statistically significant and clinically meaningful improvements in overall survival and progression-free survival (PFS) in heavily pretreated, unresectable, locally advanced or metastatic triple-negative breast cancer and recurrent or metastatic esophageal squamous cell carcinoma.
Camzyos® (mavacamten)
June 1
The FDA accepted for priority review a supplemental New Drug Application (sNDA) for Camzyos as a potential treatment for adolescents ages 12 to <18 years with symptomatic obstructive hypertrophic cardiomyopathy. The sNDA submission was based on data from the Phase 3 SCOUT-HCM trial.
Opdivo® (nivolumab)
June 1
The European Commission (EC) approved Opdivo in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and adolescent patients 12 years of age and older with previously untreated Stage III or IV classical Hodgkin Lymphoma. The EC approval is based on data from the Phase 3 SWOG 1826 (Study CA2098UT).
pumitamigMay 30
Interim Phase 2 data, announced with BioNTech SE, from the global Phase 2/3 ROSETTA Lung-02 trial evaluating pumitamig plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) demonstrated robust anti-tumor activity with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level.
mezigdomideMay 29
Announced positive results from the Phase 3 SUCCESSOR-2 trial of MeziKd versus carfilzomib and dexamethasone alone (Kd) in patients with RRMM. MeziKd demonstrated a clinically meaningful and statistically significant improvement in PFS, representing a 52% reduction in the risk of disease progression or death compared with Kd.
Sotyktu® (deucravacitinib)
May 8
The EC approved Sotyktu, alone or in combination with methotrexate, for the treatment of psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic therapy. The EC approval is based on positive results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 clinical trials.

4

Our Strategy
At Bristol Myers Squibb, our goal is to build a company that is financially strong and delivers industry-leading, sustainable growth into the 2030s and beyond.
As we advance our multi-year strategy to position the company for long-term growth, we are guided by the following priorities:
•Focusing R&D on high-impact, transformational medicines to treat life-threatening diseases;
•Embedding rigorous operational execution across the organization to build momentum in our Growth Portfolio comprised primarily of medicines early in their lifecycles; and
•Maintaining disciplined capital allocation to drive sustainable cash flow generation, balance sheet strength and long-term shareholder returns.

Business Development
The company recently entered into multiple transactions that strengthen its pipeline and operational capabilities.

In July 2026, the company announced an expansion of its existing collaboration with NVIDIA to deploy NVIDIA's newest AI infrastructure, Vera Rubin NVL72, for running predictive models at scale and training large AI models on BMS's own data. Through this latest agreement, BMS scientists have the potential to understand disease biology more deeply, design and test candidate molecules faster, and gain deeper insights from clinical outcomes sooner. We expect this to ensure the company can continue pursuing the right targets and advancing stronger candidates, ultimately working toward smarter, more targeted clinical trial design and earlier, better-informed decisions about which programs to move forward.

In May 2026, the company announced a strategic agreement with Anthropic to deploy Claude across Bristol Myers Squibb's research, clinical development, manufacturing, commercial and corporate functions. Claude will serve as the shared intelligence platform between enterprise functions, enabling the company to unlock its data and accelerate innovation.

5

Also in May 2026, the company entered into global strategic collaboration and licensing agreements with Hengrui Pharma to advance a portfolio of 13 early-stage programs in oncology, hematology and immunology. The collaboration furthers Bristol Myers Squibb's efforts to accelerate early-stage clinical development and make informed, responsible decisions that contribute to the company's growth potential.

Financial Guidance
Bristol Myers Squibb is increasing its full-year, non-GAAP revenue guidance from a range of approximately $46.0 billion to $47.5 billion to a range of approximately $49.0 billion to $50.0 billion. This update primarily reflects broad-based and continuing momentum across the portfolio.
Full-year operating expenses in 2026 are now expected to be approximately $16.5 billion, due to increased investment behind key pipeline programs and new product launches.
As a result of these guidance updates, non-GAAP EPS is increasing to an anticipated range of $6.75 - $7.00.
2026 Non-GAAP1,2 Line-Item Guidance
April
(Prior)		July
(Updated)
Total Revenues
(Reported & Ex-FX)
~$46.0 - $47.5 billion
~$49.0 - $50.0 billion
Gross Margin %~69% - 70%No change
Operating Expenses3
~$16.3 billion~$16.5 billion
Other income/(expense)~($700 million)No change
Effective tax rate
~18%
No change
Diluted EPS
$6.05 - $6.35
$6.75 - $7.00
1 See "Use of Non-GAAP Financial Information."
2 April was calculated based on mid-April 2026 foreign exchange rates, and July was calculated based on mid-July exchange rates.
3 Operating Expenses = SG&A and R&D.

The company continues to expect total Worldwide Eliquis revenues to increase in 2026 when compared to 2025, and is raising its projected range as shown in the table below.

2026 Eliquis Revenue Guidance
April
(Prior)		July
(Updated)
2026 WW Revenue Growth*10% - 15%20% - 25%
* Compared to 2025 Worldwide Eliquis revenues.

6

The 2026 financial guidance provided excludes the impact of any potential future strategic acquisitions, divestitures, specified items that have not yet been identified and quantified, and the impact of Acquired IPRD charges and licensing income incurred after June 30, 2026. To the extent we have quantified the impact of significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights, we may update this information from time to time on our website, www.bms.com, in the "Investors" section. Non-GAAP guidance assumes exchange rates as of the date noted. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

A reconciliation of forward-looking non-GAAP measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. See "Cautionary Statement Regarding Forward-Looking Statements" and "Use of Non-GAAP Financial Information."

Conference Call Information
Bristol Myers Squibb will host a conference call today, Thursday, July 30, 2026, at 8:15 a.m. ET, during which company executives will review financial results with the investment community.
Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.
7

About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

###

For more information, contact:
Media Relations: media@bms.com
Investor Relations: investor.relations@bms.com

Use of Non-GAAP Financial Information
In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company's baseline performance, supplement or enhance management's, analysts' and investors' overall understanding of the company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods. In addition, non-GAAP gross margin, which is revenue less cost of products sold excluding certain specified items, as a percentage of revenue, non-GAAP operating expenses, which is selling, general and administrative and research and development expenses excluding certain specified items, non-GAAP selling, general and administrative expenses, which is selling, general and administrative expenses excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results.

This earnings release and the accompanying tables also provide certain revenues and expenses, as well as non-GAAP financial measures, excluding the impact of foreign exchange ("Ex-FX"). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.

Non-GAAP financial measures, such as non-GAAP earnings and related EPS information, are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult
8

to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the company’s business nor reflect the company’s underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwinding of inventory purchase price adjustments, integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, costs of acquiring a priority review voucher, divestiture gains or losses, stock compensation resulting from acquisition-related equity awards, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnerships and other investments), and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates, as well as certain other significant tax items.

Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables and will also be available on the company’s website at www.bms.com. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and EPS amounts presented are calculated from the underlying amounts.

A reconciliation of forward-looking non-GAAP financial measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.

Website Information
We routinely post important information for investors on our website, www.bms.com, in the “Investors” section. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts. We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be
9

deemed to be material information. The information contained on, or that may be accessed through, our website or social media channels is not incorporated by reference into, and is not a part of, this document. All trademarks mentioned are the property of their owners.

Cautionary Statement Regarding Forward-Looking Statements
This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the company’s 2026 financial guidance, its business development and multi-year allocation strategy, anticipated developments in the company’s pipeline, expectations with respect to the company’s future market position and the projected benefits of the company’s alliances and other business development activities. These statements may be identified by the fact that they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. No forward-looking statement can be guaranteed, and there is no assurance that the company will achieve its financial guidance and strategic objectives, that the company’s future clinical studies will support the data described in this release, that the company’s product candidates will receive necessary clinical and manufacturing regulatory approvals, that the company’s pipeline products will prove to be commercially successful, that clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes, or that contractual milestones will be achieved.

Forward-looking statements are based on current expectations and projections about the company’s future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the company’s control and could cause the company’s future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; market actions taken by private and government payers to manage drug utilization and contain costs; government actions relating to the imposition of new tariffs, trade restrictions and export regulations; the company’s ability to retain patent and market exclusivity for certain products; regulatory changes that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; the company’s ability to obtain and maintain regulatory approval for its product candidates; the possibility of difficulties and delays in product introduction and commercialization; increasing industry competition; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the company’s ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; failure to complete, or delays in completing, collaborations, acquisitions, divestitures, alliances and other portfolio actions and the failure to achieve anticipated benefits from such transactions and actions; exposure to litigation and/or regulatory actions or investigations; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the company’s suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; the impact of counterfeit or unregistered versions of the company’s products and from stolen products; product label changes or other measures that
10

could result in declining sales; safety or efficacy concerns regarding the company’s products or any product in the same class as the company’s products; the risk of cyber-attacks and unauthorized disclosure of trade secrets or other confidential data; the company’s ability to execute its financial, strategic and operational plans; the company’s ability to attract and retain key personnel; the impact of the company’s significant indebtedness; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; risks relating to the use of social media platforms; issuance of new or revised accounting standards; risks relating to public health outbreaks, epidemics and pandemics; and risks related to the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risk.

Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the company’s business and market, particularly those identified in the cautionary statement and risk factors discussion in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by the company’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
11

BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited, dollars and shares in millions except per share data)

 Three Months Ended June 30,Six Months Ended June 30,
 2026202520262025
Net product sales$12,588 $11,909 $23,756 $22,794 
Alliance and other revenues385 360 706 676 
Total Revenues12,973 12,269 24,462 23,470 
Cost of products sold(a)
3,726 3,372 7,146 6,404 
Selling, general and administrative1,826 1,713 3,443 3,297 
Research and development2,959 2,580 5,608 4,837 
Acquired IPRD— 1,508 94 1,695 
Amortization of acquired intangible assets437 830 874 1,660 
Other (income)/expense, net(61)494 (28)833 
Total Expenses8,887 10,496 17,137 18,726 
Earnings/(Loss) Before Income Taxes4,086 1,773 7,326 4,744 
Income tax provision770 460 1,331 969 
Net Earnings/(Loss)3,316 1,313 5,994 3,775 
Noncontrolling Interest(1)2 — 9 
Net Earnings/(Loss) Attributable to BMS $3,317 $1,310 $5,994 $3,766 
Weighted-Average Common Shares Outstanding:
Basic2,042 2,035 2,040 2,033 
Diluted2,048 2,038 2,048 2,039 
Earnings/(Loss) per Common Share:
Basic$1.62 $0.64 $2.94 $1.85 
Diluted1.62 0.64 2.93 1.85 
Other (income)/expense, net
Interest expense
$407 $485 $818 $979 
Royalty income - divestitures— (286)— (558)
Royalty and licensing income(186)(162)(381)(421)
Investment income(101)(139)(205)(277)
Provision for restructuring56 223 61 356 
Litigation and other settlements5 1 8 259 
Contingent consideration
— 336 — 336 
Equity investment (gains)/losses
(114)22 (248)100 
Integration expenses17 32 36 74 
Divestiture (gains)/losses(138)1 (162)(7)
Other(6)(19)45 (6)
Other (income)/expense, net$(61)$494 $(28)$833 
(a)     Excludes amortization of acquired intangible assets.

12

BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUES
FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025
(Unaudited, dollars in millions)

 Change vs. 2025
 20262025GAAPExcl. F/X**
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
Growth Portfolio
Opdivo$1,417 $1,068 $2,485 $1,506 $1,053 $2,560 (6)%1 %(3)%(6)%(1)%(4)%
Opdivo Qvantig206 55 261 28 1 30 >200%>200%>200%>200%>200%>200%
Orencia801 233 1,034 711 252 963 13 %(8)%7 %13 %(8)%7 %
Yervoy481 288 769 451 277 728 7 %4 %6 %7 %2 %5 %
Reblozyl593 142 735 453 114 568 31 %24 %29 %31 %24 %29 %
Breyanzi354 131 484 255 88 344 39 %48 %41 %39 %47 %41 %
Opdualag294 55 349 252 32 284 17 %72 %23 %17 %65 %22 %
Camzyos310 105 416 214 46 260 45 %129 %60 %45 %124 %59 %
Zeposia116 53 169 105 46 150 11 %17 %12 %11 %14 %12 %
Sotyktu51 36 87 43 27 70 19 %30 %23 %19 %27 %23 %
Krazati47 8 55 47 2 48 1 %>200%14 %1 %>200%14 %
Cobenfy
60 3 63 35 — 35 73 %>200%81 %73 %>200%81 %
Other Growth Products(a)
244 409 653 248 309 557 (1)%32 %17 %(1)%32 %17 %
Total Growth Portfolio
4,974 2,585 7,560 4,348 2,248 6,596 14 %15 %15 %14 %13 %14 %
Legacy Portfolio
Eliquis3,357 1,124 4,481 2,654 1,027 3,680 27 %9 %22 %27 %7 %21 %
Revlimid352 72 425 732 106 838 (52)%(32)%(49)%(52)%(30)%(49)%
Pomalyst/Imnovid131 73 204 584 124 708 (78)%(41)%(71)%(78)%(38)%(71)%
Sprycel52 35 88 68 52 120 (23)%(32)%(27)%(23)%(30)%(26)%
Abraxane12 43 55 33 72 105 (62)%(40)%(47)%(62)%(40)%(47)%
Other Legacy Products(b)
112 58 170 100 123 223 12 %(53)%(24)%12 %(53)%(24)%
Total Legacy Portfolio
4,017 1,405 5,422 4,171 1,503 5,673 (4)%(7)%(4)%(4)%(7)%(5)%
Other Revenues(c)
— (9)(9)— — — N/AN/AN/AN/AN/AN/A
Total Revenues$8,991 $3,982 $12,973 $8,519 $3,750 $12,269 6 %6 %6 %6 %5 %5 %
**    See "Use of Non-GAAP Financial Information".
(a)    Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.
(b)    Includes other mature brands.
(c)    Includes revenue hedging activities in 2026.
(d)    Worldwide (WW) includes U.S. and International (Int'l).
13

BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUES
FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(Unaudited, dollars in millions)

 Change vs. 2025
 20262025GAAPExcl. F/X**
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
U.S.
Int'l
WW(d)
Growth Portfolio
Opdivo$2,575 $2,056 $4,631 $2,838 $1,986 $4,824 (9)%4 %(4)%(9)%(1)%(6)%
Opdivo Qvantig337 86 424 37 1 38 >200%>200%>200%>200%>200%>200%
Orencia1,391 461 1,852 1,266 467 1,733 10 %(1)%7 %10 %(4)%6 %
Yervoy848 572 1,420 845 507 1,351 — %13 %5 %— %8 %3 %
Reblozyl1,032 258 1,291 843 203 1,046 22 %27 %23 %22 %23 %23 %
Breyanzi645 250 896 459 148 607 41 %69 %48 %41 %64 %46 %
Opdualag540 103 644 480 56 537 13 %83 %20 %13 %72 %19 %
Camzyos539 190 729 340 79 419 59 %140 %74 %59 %129 %72 %
Zeposia185 102 287 166 92 257 12 %12 %12 %12 %6 %10 %
Sotyktu87 69 156 75 51 126 15 %36 %24 %15 %30 %21 %
Krazati93 11 105 91 5 96 3 %119 %9 %3 %109 %8 %
Cobenfy
116 3 119 62 — 62 88 %>200%92 %88 %>200%92 %
Other Growth Products(a)
456 778 1,234 481 583 1,063 (5)%33 %16 %(5)%32 %15 %
Total Growth Portfolio
8,846 4,940 13,787 7,982 4,178 12,159 11 %18 %13 %11 %14 %12 %
Legacy Portfolio
Eliquis6,434 2,183 8,617 5,299 1,946 7,245 21 %12 %19 %21 %6 %17 %
Revlimid630 143 773 1,541 233 1,774 (59)%(39)%(56)%(59)%(38)%(56)%
Pomalyst/Imnovid569 147 717 1,121 245 1,366 (49)%(40)%(48)%(49)%(39)%(47)%
Sprycel88 72 160 194 101 295 (54)%(29)%(46)%(54)%(28)%(45)%
Abraxane24 81 105 73 137 210 (67)%(41)%(50)%(67)%(41)%(50)%
Other Legacy Products(b)
186 140 326 182 239 421 2 %(41)%(23)%2 %(43)%(23)%
Total Legacy Portfolio
7,933 2,766 10,699 8,411 2,900 11,311 (6)%(5)%(5)%(6)%(9)%(6)%
Other Revenues(c)
— (23)(23)— — — N/AN/AN/AN/AN/AN/A
Total Revenues$16,779 $7,683 $24,462 $16,392 $7,078 $23,470 2 %9 %4 %2 %5 %3 %
**    See "Use of Non-GAAP Financial Information".
(a)    Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.
(b)    Includes other mature brands.
(c)    Includes revenue hedging activities in 2026.
(d)    Worldwide (WW) includes U.S. and International (Int'l).
14

BRISTOL-MYERS SQUIBB COMPANY
INTERNATIONAL REVENUES
FOREIGN EXCHANGE IMPACT (%)
(Unaudited)

Three Months Ended June 30, 2026Six Months Ended June 30, 2026
Revenue Change %F/X % Favorable/ (Unfavorable) **Revenue Change % Ex- F/X **Revenue Change %F/X % Favorable/ (Unfavorable) **Revenue Change % Ex- F/X **
Growth Portfolio
Opdivo1%2%(1)%4%4%(1)%
Opdivo Qvantig>200%NM>200%>200%NM>200%
Orencia(8)%1%(8)%(1)%3%(4)%
Yervoy4%2%2%13%4%8%
Reblozyl24%1%24%27%4%23%
Breyanzi48%—%47%69%6%64%
Opdualag72%6%65%83%11%72%
Camzyos129%5%124%140%10%129%
Zeposia17%2%14%12%6%6%
Sotyktu30%2%27%36%5%30%
Krazati>200%NM>200%119%10%109%
Cobenfy
>200%NM>200%>200%NM>200%
Other Growth Products(a)
32%—%32%33%2%32%
Total Growth Portfolio
15%2%13%18%4%14%
Legacy Portfolio
Eliquis9%2%7%12%6%6%
Revlimid(32)%(2)%(30)%(39)%—%(38)%
Pomalyst/Imnovid(41)%(3)%(38)%(40)%(1)%(39)%
Sprycel(32)%(2)%(30)%(29)%(1)%(28)%
Abraxane(40)%—%(40)%(41)%1%(41)%
Other Legacy Products(b)
(53)%—%(53)%(41)%1%(43)%
Total Legacy Portfolio(7)%1%(7)%(5)%4%(9)%
Other Revenues(c)
N/AN/AN/AN/AN/AN/A
Total Revenues6%1%5%9%4%5%
NM    Not meaningful
**    See "Use of Non-GAAP Financial Information".
(a)    Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.
(b)    Includes other mature brands.
(c)    Includes revenue hedging activities in 2026.

15

BRISTOL-MYERS SQUIBB COMPANY
WORLDWIDE REVENUES(a)
FOREIGN EXCHANGE IMPACT (%)
(Unaudited)

Three Months Ended June 30, 2026Six Months Ended June 30, 2026
Revenue Change %F/X % Favorable/ (Unfavorable) **Revenue Change % Ex- F/X **Revenue Change %F/X % Favorable/ (Unfavorable) **Revenue Change % Ex- F/X **
Growth Portfolio
Opdivo(3)%1%(4)%(4)%2%(6)%
Opdivo Qvantig>200%NM>200%>200%NM>200%
Orencia7%—%7%7%1%6%
Yervoy6%1%5%5%2%3%
Reblozyl29%—%29%23%1%23%
Breyanzi41%—%41%48%1%46%
Opdualag23%1%22%20%1%19%
Camzyos60%1%59%74%2%72%
Zeposia12%1%12%12%2%10%
Sotyktu23%1%23%24%2%21%
Krazati14%—%14%9%1%8%
Cobenfy81%—%81%92%—%92%
Other Growth Products(b)
17%—%17%16%1%15%
Total Growth Portfolio
15%1%14%13%1%12%
Legacy Portfolio
Eliquis22%1%21%19%2%17%
Revlimid(49)%—%(49)%(56)%—%(56)%
Pomalyst/Imnovid(71)%(1)%(71)%(48)%—%(47)%
Sprycel(27)%(1)%(26)%(46)%—%(45)%
Abraxane(47)%—%(47)%(50)%—%(50)%
Other Legacy Products(c)
(24)%—%(24)%(23)%1%(23)%
Total Legacy Portfolio
(4)%—%(5)%(5)%1%(6)%
Other Revenues(d)
N/AN/AN/AN/AN/AN/A
Total Revenues6%—%5%4%1%3%
NM    Not meaningful
**    See "Use of Non-GAAP Financial Information".
(a)    Worldwide (WW) includes U.S. and International (Int'l).
(b)    Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.
(c)    Includes other mature brands.
(d)    Includes revenue hedging activities in 2026.


16

BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
(Unaudited, dollars in millions)

 Three Months Ended June 30,Six Months Ended June 30,
 2026202520262025
Inventory purchase price accounting adjustments$13 $13 $25 $25 
Site exit and other costs2 3 2 5 
Cost of products sold15 16 28 30 
Acquisition related charges— 19 — 19 
Site exit and other costs— 3 — 5 
Selling, general and administrative— 22 — 23 
IPRD impairments 420 300 830 300 
Priority review voucher220 — 220 — 
Site exit and other costs 3 18 5 39 
Research and development643 318 1,055 339 
Amortization of acquired intangible assets437 830 874 1,660 
Interest expense
(9)(12)(18)(24)
Provision for restructuring56 223 61 356 
Litigation and other settlements— — — 246 
Contingent consideration
— 336 — 336 
Equity investment (gains)/losses(114)21 (248)98 
Integration expenses17 32 36 74 
Divestiture (gains)/losses(136)1 (160)(7)
Other— — 3 13 
Other (income)/expense, net(187)602 (327)1,091 
Increase to earnings/(loss) before income taxes908 1,788 1,630 3,143 
Income taxes on items above(53)(114)(215)(257)
Increase to net earnings/(loss) attributable to BMS$855 $1,674 $1,415 $2,887 


17

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
(Unaudited, dollars and shares in millions except per share data)

Three Months Ended June 30, 2026Six Months Ended June 30, 2026
GAAP
Specified Items(a)
Non-GAAPGAAP
Specified Items(a)
Non-GAAP
Cost of products sold
$3,726 $(15)$3,711 $7,146 $(28)$7,119 
Selling, general and administrative1,826 — 1,826 3,443 — 3,442 
Research and development2,959 (643)2,316 5,608 (1,055)4,554 
Amortization of acquired intangible assets437 (437)— 874 (874)— 
Other (income)/expense, net(61)187 126 (28)327 299 
Earnings/(Loss) before income taxes4,086 908 4,994 7,326 1,630 8,955 
Income tax provision770 53 823 1,331 215 1,546 
Net earnings/(loss) attributable to BMS used for diluted EPS calculation$3,317 $855 $4,172 $5,994 $1,415 $7,409 
Weighted-average common shares outstanding—diluted2,048 2,048 2,048 2,048 2,048 2,048 
Diluted earnings/(loss) per share$1.62 $0.42 $2.04 $2.93 $0.69 $3.62 
Gross margin(b)
71.3 %0.1 %71.4 %70.8 %0.1 %70.9 %
Effective tax rate18.8 %(2.4)%16.5 %18.2 %(0.9)%17.3 %
Three Months Ended June 30, 2025Six Months Ended June 30, 2025
GAAP
Specified Items(a)
Non-GAAPGAAP
Specified Items(a)
Non-GAAP
Cost of products sold
$3,372 $(16)$3,356 $6,404 $(30)$6,374 
Selling, general and administrative1,713 (22)1,691 3,297 (23)3,274 
Research and development2,580 (318)2,263 4,837 (339)4,498 
Amortization of acquired intangible assets830 (830)— 1,660 (1,660)— 
Other (income)/expense, net494 (602)(108)833 (1,091)(258)
Earnings/(Loss) before income taxes1,773 1,788 3,561 4,744 3,143 7,887 
Income tax provision460 114 573 969 257 1,226 
Net earnings/(loss) attributable to BMS used for diluted EPS calculation$1,310 $1,674 $2,985 $3,766 $2,887 $6,653 
Weighted-average common shares outstanding—diluted2,038 2,038 2,038 2,039 2,039 2,039 
Diluted earnings/(loss) per share$0.64 $0.82 $1.46 $1.85 $1.42 $3.26 
Gross margin(b)
72.5 %0.1 %72.6 %72.7 %0.1 %72.8 %
Effective tax rate25.9 %(9.8)%16.1 %20.4 %(4.9)%15.5 %
(a) Refer to the Specified Items schedule above for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP
effective tax rate.
(b)    Gross margin represents Revenue less Cost of products sold, as a percentage of Revenues.

18


BRISTOL-MYERS SQUIBB COMPANY
NET DEBT CALCULATION
AS OF JUNE 30, 2026 AND DECEMBER 31, 2025
(Unaudited, dollars in millions)
 
June 30,
2026		December 31,
2025
Cash and cash equivalents$8,722 $10,209 
Marketable debt securities - current2,345 464 
Marketable debt securities - non-current397 396 
Cash, cash equivalents and marketable debt securities$11,464 $11,069 
Short-term debt obligations(1,027)(2,261)
Long-term debt(42,093)(42,850)
Net debt position$(31,656)$(34,043)


19
Not for Product Promotional Use Q2 2026 Results July 30, 2026

 

Not for Product Promotional UseQ2 2026 Results Forward Looking Statements and Non-GAAP Financial Information 2 This presentation (as well as the oral statements made with respect to information contained herein) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to: (i) new laws, government actions, agreements and regulations, including with respect to pricing controls and market access and the imposition of new tariffs, trade restrictions and export regulations, including the potential for international reference pricing and most-favored nation drug pricing for our products, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) political and financial instability, including changes in general economic conditions, and (viii) risks related to the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risk. These and other important factors are discussed in the Company’s most recent annual report on Form 10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and Exchange Commission’s website, on the Company’s website or from Bristol- Myers Squibb Investor Relations. No forward-looking statements can be guaranteed. In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise. This presentation includes certain non-generally accepted accounting principles (“GAAP”) financial measures that we use to describe the Company’s performance. The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company’s baseline performance, supplement or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods. This presentation also provides certain revenues and expenses excluding the impact of foreign exchange (“Ex-FX”). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current- period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results. The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable financial measure are available on our website at www.bms.com/investors. Also note that a reconciliation of forward-looking non-GAAP measures, including non-GAAP earnings per share (EPS), to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. Certain information presented in the accompanying presentation may not add due to the use of rounded numbers.

 

3 Q2 2026 Results Chris Boerner, PhD Board Chair and Chief Executive Officer

 

Not for Product Promotional UseQ2 2026 Results Q2 2026 Performance *See “Forward-Looking Statements and Non-GAAP Financial Information” 1. Not an exhaustive list of assets, programs, or indications $6.6 $7.6 Q2 2025 Q2 2026 $ in billions 4 Growth Portfolio Revenues Key Milestones1 +15%; +14% Ex-FX* Diverse portfolio of growth drivers ASCO Data highlighted the breadth of innovation across our oncology franchise CELMoDs: advancing towards commercialization Iberdomide PDUFA: August 17, 2026 Mezigdomide PDUFA: May 13, 2027 Iza-bren Initiating 4th global pivotal trial in 1L EGFRmut NSCLC Pumitamig Initiating Phase 2 novel combination study with imzokitug

 

Q2 2026 Results Not for Product Promotional Use Significant data expected in 2026…and beyond* NME registrational data 2026 • Admilparant IPF (ALOFT-IPF) • Arlo-cel 4L+ MM (QUINTESSENTIAL) • Iberdomide RRMM PFS (EXCALIBER-RRMM) • Mezigdomide RRMM (SUCCESSOR-2) (Mar’26) • Milvexian SSP (LIBREXIA-STROKE1) • RYZ101 2L+ GEP-NETs (ACTION-1) 2027 • Golcadomide High-Risk 1L LBCL (GOLSEEK-1) • Milvexian AF (LIBREXIA-AF1) • Zola-cel SLE (Breakfree-SLE) 2028 • Atigotatug + nivolumab 1L ES-SCLC (TIGOS) • Iza-bren 1L TNBC (IZABRIGHT-Breast01) • Pumitamig 1L ES-SCLC (ROSETTA-Lung-012) LCM pivotal data 2026 • Sotyktu SLE (POETYK SLE-1 & 2) 2027 • Admilparant PPF (ALOFT-PPF) • Cobenfy AD Psychosis (ADEPT) • Cobenfy Bipolar-I (BALSAM-1 & 2) • Mezigdomide RRMM (SUCCESSOR-1) • Sotyktu Sjogren’s Disease (POETYK SjS-1) 2028 • Arlo-cel 2-4L MM (QUINTESSENTIAL-2) • Cobenfy AD Agitation (ADAGIO-2) • Cobenfy AD Cognition (MINDSET-1 & 2) • Cobenfy Adjunctive Bipolar-1 (BALSAM-4) • Golcadomide 2L+ FL (GOLSEEK-4) • Iza-bren EGFRm NSCLC (IZABRIGHT-Lung01) • Krazati 1L NSCLC (KRYSTAL-4) • Krazati 1L NSCLC PD-L1 ≥50% (KRYSTAL-7) • Reblozyl 1L NTD MDS Associated Anemia (ELEMENT) • Zola-cel SSc (Breakfree-SSc) Key next wave early-stage data 2026 • BCMAxGPRC5D dual-targeting CAR T RRMM • Golcadomide 1L FL (GOLSEEK-2) • Imzokitug (anti-CCR8) Solid Tumors • Delocamten (MYK-224) HFpEF (AURORA) • Navlimetostat (PRMT5 inhibitor) Solid Tumors • Pumitamig Solid Tumors2 • Zola-cel Autoimmune Diseases (Breakfree-1 & 2) 2027 • Moponetug (anti-MTBR-tau) Alzheimer’s Disease (TargetTau-1) • Irafamdastat (FAAH/MAGL) AD Agitation (BALANCE-AAD-1) • Irafamdastat (FAAH/MAGL) MS Spasticity (BALANCE-MSS-1) *See “Forward-Looking Statements and Non-GAAP Financial Information”, NME: New Molecular Entity, LCM: Life Cycle Management; 1. Trial conducted by Johnson & Johnson; 2. Trial conducted by BioNTech. Studies shown with dates in parenthesis have reported readouts 5

 

Q2 2026 Results Not for Product Promotional Use Rewiring how we operate* AI-Powered Execution Expanding AI to help teams move faster and operate more efficiently, further strengthened through our Anthropic & NVIDIA partnerships Operating Discipline Company-wide savings through strategic productivity initiative, combined with strong free cash flow and balance sheet strength Financial Flexibility Invest in growth drivers, pursue strategic business development opportunities, and return cash to shareholders 6 *See “Forward-Looking Statements and Non-GAAP Financial Information”

 

7 Q2 2026 Results David Elkins Executive Vice President and Chief Financial Officer

 

Q2 2026 Results Not for Product Promotional Use $ in billions Growth Portfolio continues to drive revenues Other Growth Brands1 Growth Portfolio Legacy Portfolio Other Mature Brands $6.6 $7.6 5.7 5.4 Q2 2025 Q2 2026 $12.3 $13.0 +15% YoY +14% Ex-FX* 8 *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Other Growth Brands: Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg, & Royalty Revenues, including royalties received from Merck on Winrevair

 

Not for Product Promotional UseQ2 2026 Results Q2 2026 Oncology product summary *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Abraxane: Q2 2026 WW Sales $55M - YoY% (47%), (47%) Ex-FX*; 2. Opdivo Q2’26 global sales reflect ~$200M sequential inventory build Global Net Sales1 $M YoY % Ex-FX* % $2,485 (3%) (4%) $769 +6% +5% $349 +23% +22% $261 >200% >200% $55 +14% +14% Opdivo • Remains an important revenue contributor to the Growth Portfolio and continues to deliver value to patients 9 Qvantig • Continued global growth is driven by meaningful convenience to patients and healthcare systems Opdualag • Growth reflects strong demand and established position as a standard of care in 1L melanoma 2

 

Not for Product Promotional UseQ2 2026 Results Global Net Sales1 $M YoY % Ex-FX* % $735 +29% +29% $484 +41% +41% $425 (49%) (49%) $204 (71%) (71%) Q2 2026 Hematology product summary *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Abecma: Q2 2026 WW Sales $72M - YoY% (17%), (16%) Ex-FX*; Sprycel: Q2 2026 WW Sales $88M - YoY% (27%), (26%) Ex-FX*; 2. In the U.S., generic lenalidomide products are no longer volume-limited as of January 31, 2026; 3. In the U.S., generic pomalidomide entered in March of 2026 Reblozyl • Growth driven by continued global demand across MDS-associated anemia, with the predominant share in 1L 10 3 2 Breyanzi • Continued strong demand as the leading CD19 directed CAR T across B-cell malignancies, focused on growing adoption in the community outpatient setting

 

Not for Product Promotional UseQ2 2026 Results Q2 2026 Cardiovascular & Immunology product summary Global Net Sales (Cardiovascular) $M YoY % Ex-FX* % $4,481 +22% +21% $416 +60% +59% *See “Forward-Looking Statements and Non-GAAP Financial Information” Eliquis • Continued U.S. demand growth and market share gains Camzyos • Continued strong global demand and market penetration in oHCM • Strong launch momentum outside the U.S. 11 Global Net Sales (Immunology) $M YoY % Ex-FX* % $1,034 +7% +7% $87 +23% +23% Sotyktu • Continued engagement with the rheumatology community ahead of pivotal SLE and SjD readouts

 

Not for Product Promotional UseQ2 2026 Results Q2 2026 Neuroscience product summary Global Net Sales $M YoY % Ex-FX* % $169 +12% +12% $63 +81% +81% Cobenfy • Steady growth trajectory expected near term • Improving patient experience through prescriber education emphasizing optimized dose utilization *See “Forward-Looking Statements and Non-GAAP Financial Information” 12

 

Not for Product Promotional UseQ2 2026 Results US GAAP Non-GAAP $ in billions, except EPS Q2 2026 Q2 2025 Q2 2026 Q2 2025 Total Revenues, net 13.0 12.3 13.0 12.3 Gross Margin %1 71.3% 72.5% 71.4% 72.6% Operating Expenses2 4.8 4.3 4.1 4.0 Acquired IPR&D - 1.5 - 1.5 Amortization of Acquired Intangibles 0.4 0.8 - - Effective Tax Rate 18.8% 25.9% 16.5% 16.1% Diluted EPS 1.62 0.64 2.04 1.46 Diluted Shares Outstanding (# in millions) 2,048 2,038 2,048 2,038 Q2 2026 Financial Performance GA P Non- P* Diluted EPS Impact from Acquired IPR&D3 0.01 (0.57) 0.01 (0.57) *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Gross Margin = Revenue less COGS as a percentage of Revenue; 2. Operating Expenses = SG&A and R&D; 3. Represents the net impact from Acquired IPRD & licensing income 13

 

Not for Product Promotional UseQ2 2026 Results Strategic approach to Capital Allocation 1. Cash includes cash, cash equivalents and marketable debt securities; 2. Subject to Board approval Cash flow from Operations $B 14 $3.9 $6.3 $2.0 $1.1 $3.4 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 $B Q2 2026 Total Cash1 ~$11.5 Total Debt ~$43.1 Business Development • Pursue opportunities and partnerships to diversify portfolio & strengthen long-term outlook Balance Sheet Strength • Strong balance sheet affords financial flexibility • Maintain strong investment-grade credit rating Returning Cash to Shareholders • Remain committed to our dividend2 • ~$5B share repurchase authorization remaining as of June 30, 2026

 

Not for Product Promotional UseQ2 2026 Results 2026 Guidance* 15 *The Company does not reconcile forward-looking non-GAAP measures. See “Forward-Looking Statements and Non-GAAP Financial Information”; 2026 Guidance excludes the impact of any potential strategic acquisitions, divestitures, specified items that have not yet been identified and quantified, and the impact of future Acquired IPRD charges and licensing income incurred after June 30, 2026; 1. Guidance provided in April was calculated based on mid-April foreign exchange rates; Guidance provided in July was calculated based on mid-July foreign exchange rates; 2. Operating Expenses = SG&A and R&D Non-GAAP1 April (Prior) July (Updated) Total FY Revenues (Reported & Ex-FX) ~$46.0 - $47.5B ~$49.0 - $50.0B Gross Margin % ~69-70% No change Operating Expenses2 ~$16.3B ~$16.5B Other Income/ (Expense) ~($700M) No change Tax Rate ~18% No change Diluted EPS $6.05 - $6.35 $6.75 - $7.00 • FY revenue vs. prior guidance reflects strong first half results and our current projections for the year: • Continued Growth Portfolio strength • 4% to 6% decline in Legacy Portfolio • 20% to 25% growth in WW Eliquis revenue • Gross margin reflects impact of product mix • Operating expenses increase reflects growth-oriented initiatives Diluted weighted-average shares outstanding of 2,050 million were used to calculate 2026 diluted EPS guidance Key Highlights

 

Chris Boerner, PhD Board Chair, Chief Executive Officer David Elkins Executive VP, Chief Financial Officer Adam Lenkowsky Executive VP, Chief Commercialization Officer Cristian Massacesi, MD Executive VP, Chief Medical Officer, Global Drug Development Q2 2026 Results Q&A

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Press Releases

Other Documents